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injected AC133 stem cells in 4 patients was 38.2, 141, 170, 51.3
million, and 28 million of CD34 cells in 1 patient. Three patients
underwent percutaneous intramuscular AC133 stem cell trans-
plant into the right LE, 2 patients into the left LE. Injection sites
were marked by ultrasound and were 4 to 20 sites per extremity.
There were no complications associated with the procedure. Me-
dian follow-up after the transplant is 4 (range 1.5–11) months. First
patient with very advanced LE ischemia, unfortunately, was in-
volved into study too late as ischemia continued to progress and
eventually patient required a below-knee amputation. Second pa-
tient with Burger’s disease, now 7.5 months after the transplant,
has had signiﬁcant improvement in symptoms such as rest pain and
claudication. Objective testing at 3- and 6-month follow-up
showed improvement in all parameters, including detectable new
faint posterior tibialis (PT) artery pulse, improved four-meter and
six-minute walk tests, walking impairment questionnaire, Gardner
graded treadmill test, and Doppler arterial brachial index, dorsalis
pedis (DP), and PT values increasing from 0.34, 28, 37 to 0.37, 37,
43, respectively. Additionally, MRA of LE showed increasing num-
ber of collateral vessels in a diseased calf. Last 3 patients had a short
follow-up with no objective testing repeated, although all of them
reported marked symptom improvement and increased walking
capacity. In last 2 patients, we detected faint DP and PT pulses,
which were absent before procedure. Our preliminary data suggest
that AC133 stem cell percutaneous transplant can be performed
safely and appears to be beneﬁcial therapy for selected patients
with severe peripheral vascular disease.
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LEUKOCYTE AND PLATELET COUNTS CAN BE USED TO GUIDE COL-
LECTION OF AUTOLOGOUS STEM CELLS AFTER G-CSF MOBILIZATION
ON THE FIRST TWO DAYS OF LEUKAPHERESIS BUT NOT BEYOND
Gidron, A.1, Mehta, J.1 Division of Hematology/Oncology, Northwest-
ern University, Chicago, IL.
When donors are treated with G-CSF to collect stem cells for
allogeneic transplantation, the combination of a pre-apheresis leu-
kocyte count of 25  109/L anda pre-apheresis platelet count of
100  109/L is associated with excellent mobilization as mea-
sured by an absolute peripheral blood CD34 cell count
(PBCD34) of 20/L, and can be used to guide harvest timing
(Tomblyn et al Bone Marrow Transplantation advance online
publication 01 August 2005; doi: 10.1038/sj.bmt.1705117). We
wanted to see if this observation could be extended to patients
receiving 10–16 g/kg G-CSF daily as the sole mobilizing agent
for autologous stem cell collection. Data from 161 leukapheresis
procedures (65 day 1 collections, 47 day 2 collections, and 49
collections done beyond day 2) were analyzed to determine corre-
lation between pre-apheresis leukocytes, platelets, and PBCD34.
Overall, when leukocytes 25 and platelets 100, PBCD34 was
2.9–515.5 (median 31.8); signiﬁcantly (P  .0001) higher than
PBCD34 of 0.6–226.0 (median 6.0) when leukocytes were 25
and/or platelets were 100. Among day 1 collections, with leuko-
cytes 25 and platelets 100, PBCD34 was 20 and 10 in 63% and
78% of the time compared to 16% and 36% of the time if
leukocytes were 25 and/or platelets were 100 (P  .0001 and
P  .001, respectively). Similarly, PBCD34 levels of 20 and 10
were obtained 63% and 87% of the time with day 2 collections
when leukocytes were 25 and platelets 100, compared with
19% and 35% of the time when leukocytes were 25 and/or
platelets were100 (P .003 and 0.001, respectively). Beyond day
2, when leukocytes 25 and platelets 100, PBCD34 was 20 50%
of the time compared with 7% when leukocytes were 25 and/or
platelets were 100 (P  .047). Our data suggest that in patients
with hematologic malignancies receiving G-CSF for mobilization
of autologous stem cells, the combination of a leukocyte count of
25 and a platelet count of 100 is associated with excellent
mobilization of stem cells in the majority of patients on the ﬁrst
and second harvest days but not beyond. Conversely, lower leuko-
cyte and/or platelet counts predict for poor mobilization beyond
the second day, but not on the ﬁrst two days. Thus, on the ﬁrst and
second days of stem cell collection in patients mobilized with
G-CSF, apheresis can be initiated based on favorable hematologic
parameters without necessarily awaiting PBCD34 levels. However,
beyond the second day, PBCD34 levels should guide apheresis.
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SYNGENEIC NEUROBLASTOMA CELLS TRANSIENTLY-TRANSFECTED
WITH PLASMID DNA VECTORS ENCODING A PANEL OF IMMUNE STIM-
ULATORY MOLECULES CAN INDUCE ANTI-TUMOR IMMUNITY EARLY
AFTER BMT
Jing, W.1, Yan, X.1, Orentas, R.J.1, Johnson, B.D.1 Medical College of
Wisconsin, Milwaukee, WI.
Mouse neuroblastoma (Neuro-2a) cells genetically modiﬁed to
express CD54 (ICAM-1), CD80, CD86, and CD137L (4-1BB
ligand) can serve as a tumor vaccine. The goals of this study were
to determine the cellular components required to induce tumor-
protective immunity with this vaccine early after syngeneic bone
marrow transplantation (BMT), and to determine if the cell-based
vaccine could prevent tumor growth in a minimal residual disease
model. Lethally irradiated A/J mice were transplanted with synge-
neic BM cells with or without puriﬁed T cells or splenocytes (as a
source of T cells). The Neuro-2a-based vaccine was given to
transplant recipients on days 7 and 14 post-transplant. Vaccination
of mice given BM without added T cells failed to protect mice from
a challenge of 105 or 106 viable tumor cells. In contrast, 79% of
vaccinated mice given T cells at the time of BMT survived tumor
challenge. Development of protective immunity was dependent
upon both CD4 and CD8 T cells. We concluded that the
adoptive transfer of T cells was absolutely required for induction of
tumor vaccine-induced protective immunity. We examined
whether depletion of CD25 regulatory T cells from the adop-
tively-transferred T cells or in vivo CD25 depletion of the trans-
plant recipients would further increase vaccine-induced tumor im-
munity, but they did not. This suggests that the lethal conditioning
itself had eliminated the majority of CD25 regulatory T cells. To
more closely mimic treatment of “minimal” residual disease, A/J
mice transplanted with BM and splenocytes were inoculated with
104 AGN2a cells one day after BMT. Tumor vaccination was
administered on days 2 and 9 post-BMT. Tumor vaccination in
this model failed to protect mice from tumor progression. How-
ever, in a preliminary experiment, post-BMT vaccination with
tumor cells expressing CD54, CD80, CD86, CD137L, and IL-15
could prevent tumor progression if splenocytes given at the time of
BMT were from tumor-primed donors. Collectively, these results
demonstrate that anti-neuroblastoma immunity can be induced
early after BMT using novel cell-based cancer vaccines; however,
in a setting of minimal residual disease, a combination of adoptive
immunotherapy and tumor vaccination is required to prevent post-
transplant tumor relapse.
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MITOXANTRONE AND MELPHALAN AS A CONDITIONING REGIMEN FOR
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA
Sprague, K.A.1, Padgaonkar, V.A.1, Klein, A.K.1, Chan, G.W.1,
Miller, K.B.2, Klingemann, H.1 1. Tufts-New England Medical Center,
Boston, MA; 2. Beth Israel-Deaconess Medical Center, Boston, MA.
A variety of conditioning regimens are used for autologous he-
matopoietic stem cell transplantation in patients with acute my-
elogenous leukemia (AML). High dose mitoxantrone and melpha-
lan (Mito/Mel) has been reported as an effective and well-tolerated
regimen for autologous peripheral blood stem cell transplantation
(APBSCT) in patients with lymphoma. We review our experience
with Mito/Mel as a conditioning regimen in 18 adult patients (12
female, 6 male) with intermediate or high risk AML who under-
went APBSCT. All patients received anthracycline based induction
and consolidation chemotherapy prior to APBSCT. At the time of
transplantation, 16 patients were in ﬁrst complete remission (CR)
and 2 patients were in second CR. Median age at the time of
APBSCT was 51 years (range 19–70). All patients received a
conditioning regimen consisting of mitoxantrone 60 mg/m2 IV on
day 4 and melphalan 180 mg/m2 IV on day 1, followed by
infusion of autologous peripheral blood stem cells on day 0. Rapid
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hematologic recovery was observed in most patients, with values of
ANC 	500 and platelet 	20,000 being reached at 13 and 16 days,
respectively. Cardiac toxicity was monitored by echocardiogram.
All patients demonstrated a normal left ventricular ejection frac-
tion (LVEF) prior to receiving the conditioning regimen. There
were no deaths attributable to heart failure. A signiﬁcant decline in
LVEF developed in only one patient who was over age 60 with
underlying diabetes and hypertension. Ninety-four percent of pa-
tients survived the ﬁrst 100 days following transplant. To date, 7
patients are alive and in remission at 2 to 7 years since disease
onset, with no patients lost to follow-up. The 3-year failure-free
and overall survival are 44% and 55%, respectively. We conclude
that high dose mitoxantrone and melphalan is an effective and
easily administered conditioning regimen with a low risk of signif-
icant cardiac toxicity despite prior treatment with anthracycline
based chemotherapy, and thus is a safe regimen for APBSCT in
adults with AML.
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COMPARISON OF FIXED DOSE (6 MG) PEGFILGRASTIM AND DAILY
FILGRASTIM TO ACCELERATE HEMOPOIETIC RECOVERY AFTER AU-
TOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
Marcacci, G.1, Petti, M.C.2, Ferrara, F.3, Scarpato, N.4, Storti, S.5,
D’Arena, G.1, Palombi, F.2, Palmieri, S.3, Andretta, C.4, Pinto, A.1 1.
Hematology Oncology and Bone Marrow Transplantation Unit, Na-
tional Cancer Institute, Fondazione “Pascale” IRCCS, Naples, Italy; 2.
Hematology Unit, National Cancer Institute, “Regina Elena” IRCCS,
Rome, Italy; 3. Hematology and BMT Unit, AORN “Cardarelli”,
Naples, Italy; 4. Hemapheresis Unit, AOU “Federico II”, Naples, Italy;
5. Hematology Oncology Unit, Catholic University, Campobasso, Italy.
High dose therapy plus Autologous Stem Cell Transplantation
(ASCT) is a milestone treatment program for most hematologic
malignancies. ASCO guidelines recommend the use of granulocyte
colony stimulating factors (G-CSF) in the post-infusion phase, to
shorten the period of severe neutropenia and reduce the related
risk of life-threatening infections. Thus, daily subcutaneous injec-
tions of G-CSF (ﬁlgrastim/lenograstim) at 5 g/kg dose until
ANC 	 500/l are routinely administered from day 1 following
ASCT, in order to accelerate hematopoietic recovery and to avoid
neutropenic complications. Pegﬁlgrastim, a novel long-acting re-
combinant G-CSF, has been shown to have similar efﬁcacy when
compared to G-CSF for chemotherapy-induced neutropenia, but
little is known about its use in the ASCT setting. We used a 6 mg
ﬁxed dose Pegﬁlgrastim on day 4 following ASCT in 47 patients
(23 male/24 female; median age 56 years; range 22–70 years) with
multiple myeloma (26 pts) and relapsed or refractory Hodgkin’s
and non- Hodgkin’s lymphoma (21 pts). Patients received periph-
eral CD34 stem cells (median number 4.4  106/kg; range 1.8–
1.8) harvested after mobilizing chemotherapy (cytoxan, vinorel-
bine/cytoxan, R-IEV, IGEV, R-ICE) and G-CSF. Standard
conditioning regimens (HD-Melphalan or BEAM) were used. En-
graftment results were compared to those from a historical control
group of 182 patients (median age 56 years; range 16–74 years)
who had received HD-Melphalan or BEAM and ASCT (median
CD34 cells 7.6  106/kg; range 1.8–14.6) supported by G-CSF
(5 g/kg/day from day 1 until ANC 	 500/l). Median number
of days to ANC 	 500/l were comparable between the Pegﬁl-
grastim (10, range 8–15) and G-CSF (11, range 7–22) groups, as
well as the median number of days to PLT 	 20,000/l (Pegﬁl-
grastim  12, range 9–20 vs G-CSF  12, range 7–29). Overall
infectious rates, including FUO and documented infections, were
of 48% and 39% for Pegﬁlgrastim and G-CSF groups, respectively
(P  NS). Median number of days on iv antibiotics were 0 (range
0–18) and 6 (range 0–13) for the Pegﬁlgrastim and G-CSF groups,
respectively. No signiﬁcant differences in the incidence of bone
pain, intensity of transfusion support, and length of hospital stay
were documented between the two groups. These data indicate
that a ﬁxed 6 mg single-dose of Pegﬁlgrastim is safe and effective
to accelerate engraftment after ASCT. No signiﬁcant differences
with G-CSF were apparent as to engraftment times and overall
infectious complications.
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PREDICTABILITY OF PRETRANSPLANT INTRAVENOUS BUSULFAN
(IVBU) PK DATA IN ACHIEVING TARGETED IVBU AUC’S DURING CON-
DITIONING IN AUTO BMT
Grosso, D.1, Brunner, J.1, Dessain, S.1, Ferber, A.1, Filicko, J.1,
Mookerjee, B.1, Shaw, L.M.2, Tedesco, N.1, Tran, H.3, Wagner, J.L.1,
Flomenberg, N.1 1. Thomas Jefferson University, Philadelphia, PA; 2.
University of Pennsylvania Medical Center, Philadelphia, PA; 3.M. D.
Anderson Cancer Center, Houston, TX.
Eight adult patients with hematological malignancies were enrolled
in a phase I IVBU dose-escalation trial in autologous BMT condi-
tioning. All patients received four daily doses of IVBU followed by 2
days of cyclophosphamide (CP) with amifostine cytoprotection.
There were 4 planned cohorts of patients with an increasing targeted
IVBU AUC of 20% in each subsequent cohort. The targeted average
daily AUC range for IVBU in cohort 1 was 4400–5280 uMolmin/
dose (mean 4800), the AUC range commonly achieved by single daily
doses of 3.2 mg/kg/day. PK data from 6 time points over 5 hours was
obtained from an IVBU test dose of 0.4 mg/kg administered to
patients 7 to 21 days prior to conditioning. Test dose data was used to
achieve the targeted IVBU AUC for conditioning doses 1 and 2.
IVBU PK data was also collected around conditioning doses 1 and 3
at 7 points over 20 hours. If the targeted daily AUC range was not
achieved based on the IVBU PK data for dose 1, IVBU doses were
adjusted to correct the AUC during days 3 and 4 IVBU was measured
in plasma samples using a validated gas chromatography method.
Acetaminophen and metronidazole were held during all IVBU ad-
ministration. Fungal prophylaxis was the same during IVBU test and
conditioning doses. Patients received phenytoin for seizure prophy-
laxis. All PK data followed expected pharmacokinetic behavior. In
cohort no. 1, test dose PK data resulted in achieving the targeted
AUC for 3 of 5 (60%), but in none of the 3 patients in cohort no. #2
based on ﬁrst IVBU conditioning dose PK results. The test dose PK
data resulted in a lower than targeted AUC in 5 patients. Of these 5
patients, 4 achieved the targeted 4-day AUC after dose adjustments.
Hepatic veno-occlusive disease was diagnosed in 2 patients in cohort
no. 2 after IVBU doses were increased to obtain the targeted mean
4-day AUC. The study was closed. Utilizing PK data based on a small
pretransplant IVBU test dose with limited blood sampling of up to 5
hours did not accurately predict conditioning AUCs, especially when
higher targeted AUCs were desired. PK data from ﬁrst dose IVBU
conditioning dose was more predictive of later IVBU conditioning
AUCs. This suggests that conditions during the test dose as proposed
in this study did not accurately reﬂect those of conditioning and/or
that a higher test dose with more comprehensive blood sampling
might be more predictive in estimating IVBU dose when single daily
busulfan is administered with targeting strategy (Table1).












1 4400–5280 3558 8590 6074
2 4400–5280 4864 4853 4858
3 4400–5280 5152 6232 5692
4 4400–5280 4771 4870 4820
5 4400–5280 4223 5358 4790
6 5281–6340 4034 6858 5446
7 5281–6340 4905 6586 5745
8 5281–6340 4051 6207 5129
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TANDEM HIGH DOSE THERAPY WITH HEMATOPOIETIC PROGENITOR
CELL RESCUE IN CHILDREN WITH HIGH-RISK SOLID TUMORS
Schneiderman, J.1, Hewlett, B.1, Morgan, E.1, Walterhouse, D.O.1,
Jacobsohn, D.1, Kletzel, M.1 Children’s Memorial Hospital, Chicago, IL.
A major advance in the treatment of high-risk patients with solid
tumors has been to intensify therapy. We hypothesize that the use
of tandem high dose chemotherapy followed by stem cell rescue
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